Biopolym. Cell. 2001; 17(5):441-447.
Biomedicine
The investigation of ceruloplasmin influence on the experimental myosin-induced myocardial damage
1Sidorik L. L., 1Bobyk V. I., 1Fedorkova O. M., 2Ryabenko D. V., 2Sergienko O. V., 2Trunina I. V., 3Koroleva O. V., 3Stepanova Ye. V., 3Gusarova Yu. N., 1Matsuka G. Kh.
  1. Institute of Molecular Biology and Genetics, NAS of Ukraine
    150, Akademika Zabolotnoho Str., Kyiv, Ukraine, 03680
  2. National Scientific Center "M. D. Strazhesko Institute of Cardiology, MAS of Ukraine"
    5, Narodnogo Opolchennya Str., Kyiv, Ukraine, 03151
  3. A. N. Bach Institute of Biochemistry, RAS
    33, Leninsky prospekt, build. 2, Moscow, Russian Federation, 119071

Abstract

The data on influence of different doses of ceruloplasmin on the autoimmune myosine-induced myocardial damage like dilated cardiomyopathy obtained on the mouse model are presented. The level of autoantibodies directed against the human and mouse myosins has been examined. The cardiomyocites morphological injures have been revealed by a hystochemical assay at different stages of the disease progression. We have shown dose-depended cardioprotective and immunomodulating effects of ceruloplasmin.

References

[1] Floris G, Medda R, Padiglia A, Musci G. The physiopathological significans of ceruloplasmin. A posible therapeutic approach. Biochem. Pharmacol. 2000; 60(12): 1735-41.
[2] Danzeisen R, Ponnambalam S, Lea RG, Page K, Gambling L, McArdle HJ. The effect of ceruloplasmin on iron release from placental (BeWo) cells; evidence for an endogenous Cu oxidase. Placenta. 2000;21(8):805-12.
[3] Seniuk OF, Skorobogat'ko OV, Tarasenko PD, Romashko VV, Zhuravets LA, Zadorozhnaia LV, Iaropolov AI. [Study of physiological functions of human ceruloplasmin. The effect of ceruloplasmin on immunocytes in a normal state and in pathology]. Biokhimiia. 1994;59(10):1503-10.
[4] Park YS, Suzuki K, Mumby S, Taniguchi N, Gutteridge JM. Antioxidant binding of caeruloplasmin to myeloperoxidase: myeloperoxidase is inhibited, but oxidase, peroxidase and immunoreactive properties of caeruloplasmin remain intact. Free Radic Res. 2000;33(3):261-5.
[5] Yoshida K, Kaneko K, Miyajima H, Tokuda T, Nakamura A, Kato M, Ikeda S. Increased lipid peroxidation in the brains of aceruloplasminemia patients. J Neurol Sci. 2000;175(2):91-5.
[6] Keller R, Torta R, Lagget M, Crasto S, Bergamasco B. Psychiatric symptoms as late onset of Wilson's disease: neuroradiological findings, clinical features and treatment. Ital J Neurol Sci. 1999;20(1):49-54.
[7] Daimon M, Susa S, Ohizumi T, Moriai S, Kawanami T, Hirata A, Yamaguchi H, Ohnuma H, Igarashi M, Kato T. A novel mutation of the ceruloplasmin gene in a patient with heteroallelic ceruloplasmin gene mutation (HypoCPGM). Tohoku J Exp Med. 2000;191(3):119-25.
[8] Scudder PR, Al-Timimi D, McMurray W, White AG, Zoob BC, Dormandy TL. Serum copper and related variables in rheumatoid arthritis. Ann Rheum Dis. 1978;37(1):67-70.
[9] Fox PL, Mazumder B, Ehrenwald E, Mukhopadhyay CK. Ceruloplasmin and cardiovascular disease. Free Radic Biol Med. 2000;28(12):1735-44.
[10] Iskra M, Majewski W. Activities of copper, zinc-superoxide dismutase in erythrocytes and ceruloplasmin in serum in chronic ischemia of lower limbs. Int J Clin Lab Res. 1999;29(2):64-7.
[11] Pharmindex'97-medicaments. Eds VN Kovalenko, AP Viktorova. K.: Morion, 1997; 1050 p.
[12] Caforio AL. Role of autoimmunity in dilated cardiomyopathy. Br Heart J. 1994;72(6 Suppl):S30-4.
[13] Goldman JH, McKenna WJ. Immunopathogenesis of dilated cardiomyopathies. Curr Opin Cardiol. 1995;10(3):306-11.
[14] Ryabenko DV. Dilated cardiomyopathy. 1. Epidemiology, prognosis, some etiology. Ukr Kardiol Zh. 1997;(5-6):106-9.
[15] Ryabenko DV. Dilated cardiomyopathy. 2. Virus-immunological theory: Transformation of viral myocarditis in dilated cardiomyopathy. Ukr Kardiol Zh. 1998; 1:70-6.
[16] Caforio AL, Bonifacio E, Stewart JT, Neglia D, Parodi O, Bottazzo GF, McKenna WJ. Novel organ-specific circulating cardiac autoantibodies in dilated cardiomyopathy. J Am Coll Cardiol. 1990;15(7):1527-34.
[17] Bobyk VI, Fedorkova OM, Ryabenko DV, Kovenia TV, Sidorik LL, Matsuka GKh. The ventricular and atrium cardiac myosin at dilated cardiomyopathy: a comparative study of immunoreactivity. Biopolym Cell. 1999; 15(5):395-401.
[18] Neumann DA, Lane JR, Wulff SM, Allen GS, LaFond-Walker A, Herskowitz A, Rose NR. In vivo deposition of myosin-specific autoantibodies in the hearts of mice with experimental autoimmune myocarditis. J Immunol. 1992;148(12):3806-13.
[19] Smith SC, Allen PM. Myosin-induced acute myocarditis is a T cell-mediated disease. J Immunol. 1991;147(7):2141-7.
[20] Ryabenko DV, Sidorik LL, Bobyk VI, Sergienko OV, Fedorkova OM, Trunina IV, Matsuka GKh. Morphological features of autoimmune damage of myocardium caused by various human miocardial antigens: comparative experimental examination. Ukr Reumatol Zhur. 2000; (2):55–60.
[21] Sidorik LL, Rodnin NV, Bobyk VI, Ryabenko DV, Veberov AV, Tkachenko TYu, Matsuka GKh. Investigation of autoantibodies directed against tissue-specific myocardial antigens in dilated cardiomyopathy. Biopolym Cell. 1995; 11(1):81-6.
[22] Bobik VI, Veberov AV, Ryabenko DV, Dubrovskaya GV, Rodnin NV, Sidorik LL. The purification of the main tissue-specific antigens from the normal and effected by dilatative cardiomyopathia human heart. Biopolym Cell. 1993; 9(6):63-6.
[23] Lie JT, Holley KE, Kampa WR, Titus JL. New histochemical method for morphologic diagnosis of early stages of myocardial ischemia. Mayo Clin Proc. 1971;46(5):319-27.
[24] Cellarius YuG, Semenova LA, Nepomnyaschih LM. Focal lesions and myocardial infarction: Light, polarization and electron microscopy: method. development of pathology. anatomy. Novosibirsk, 1980. 72 p.
[25] Avtandilov GG, Yabluchanskiy NI, Gudenko VG. System stereometry in the pathological process study. M.: Meditsina, 1981; 191 p.
[26] Matsiota P, Druet P, Dosquet P, Guilbert B, Avrameas S. Natural autoantibodies in systemic lupus erythematosus. Clin Exp Immunol. 1987;69(1):79-88.